Although GSK-3β is perhaps best known as a potential drug target for metabolic conditions such as type-2 diabetes and insulin resistance due to the effects of this enzyme on glycogen metabolism, GSK-3β is highly expressed in the brain and is linked to a variety of central nervous system (CNS) disease states, including AD, Huntington's disease and stroke [7, 8]. This evidence concerns the gene GSK3B and stroke disorder.